Reiss Allan L, Hall Scott S
Center for Interdisciplinary Brain Sciences Research, Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA 94305-5975, USA.
Child Adolesc Psychiatr Clin N Am. 2007 Jul;16(3):663-75. doi: 10.1016/j.chc.2007.03.001.
Fragile X syndrome (FraX) is the most common known cause of inherited mental impairment. FMR1 gene mutations, the cause of FraX, lead to reduced expression of FMR1 protein and an increased risk for a particular profile of cognitive, behavioral, and emotional dysfunction. The study of individuals with FraX provides a unique window of understanding into important disorders such as autism, social phobia, cognitive disability, and depression. This review highlights the typical phenotypic features of individuals with FraX, discussing the apparent strengths and weaknesses in intellectual functioning, as evidenced from longitudinal follow-up studies. It also discusses recent neuroanatomic findings that may pave the way for more focused disease-specific pharmacologic and behavioral interventions. This article describes the results of recent medication trials designed to target symptoms associated with FraX. It also describes some recent behavioral interventions that were conducted in our laboratory.
脆性X综合征(FraX)是已知遗传性智力障碍最常见的病因。FMR1基因突变是FraX的病因,会导致FMR1蛋白表达减少,并增加特定类型认知、行为和情感功能障碍的风险。对脆性X综合征患者的研究为了解自闭症、社交恐惧症、认知障碍和抑郁症等重要疾病提供了一个独特的窗口。本综述强调了脆性X综合征患者的典型表型特征,讨论了智力功能方面明显的优势和劣势,纵向随访研究证明了这一点。它还讨论了最近的神经解剖学发现,这些发现可能为更有针对性的针对特定疾病的药物和行为干预铺平道路。本文描述了最近旨在针对与脆性X综合征相关症状的药物试验结果。它还描述了我们实验室最近进行的一些行为干预。